Patients Coming Off Weight-Loss Jabs Gain Back Pounds Four Times Faster Compared to Dieters

Fresh analysis indicates that patients who come off popular slimming jabs like Mounjaro or Wegovy can put back on shed pounds at a significantly accelerated pace than those who stop traditional diet and exercise plans.

Research printed in a leading medical journal shows that while overweight people often shed about a fifth of their total mass while undergoing treatment, the mass comes back at an estimated rate of 0.8 kg per month after stopping.

"Users using such medications must be informed of the danger of fast weight regain when the therapy ends," warns researcher Dr. Susan Jebb.

That rate of recovery implies a return to original mass in about a year and a half.

Comparing Therapies

The study, which reviewed dozens of studies involving thousands of participants, compared the results of the injectable medications with conventional dieting.

Scientists emphasize that people who shed pounds through diet and exercise usually experience a slower weight regain—perhaps 100 grams monthly—once they finish.

Understanding the Fast Rebound

Nutrition scientists believe the mode of action of the jabs is key to understanding the amplified weight return.

GLP-1 drugs imitate a body's own chemical called glucagon-like peptide-1, which moderates hunger.

"Long-term administration of the hormone concentrations several times higher than normal might result in the body to produce less of its endogenous hormone, and could lessen sensitivity to its effects," said Dr. Adam Collins, a dietetics specialist.

"Discontinuation of this GLP-1 'fix' results in hunger is uncontrolled, making overeating much more probable."

A Lifelong Issue?

Health authorities advise the jabs for people with weight-linked health risks, accompanied by recommended lifestyle changes.

A number of clinicians say that, due to the likelihood of weight regain, the therapy might need to be ongoing.

This perspective is supported by pharmaceutical companies, who state that the findings "highlight the persistent nature of obesity," comparing it to managing diseases like hypertension.

Patient Experiences

Individuals who have stopped the jabs explain a intense return of appetite.

"It felt as if a switch activating and you become extremely hungry," described one woman.

The struggle is compounded if users have not adopted lasting dietary or behavioural changes during therapy.

Growing Adoption

Figures suggest that millions of adults in the UK have tried weight-loss jabs in the last 12 months, with desire being substantial.

• Adoption is greater among women than men.
• The middle-aged age group shows the highest level of interest.
• A large proportion access the drugs through private healthcare rather than the NHS.

Ultimately, researchers caution that while GLP-1 drugs are powerful tools for shedding pounds, they are not a permanent cure and maintained weight loss likely depends on combined behavioural management.